Therapeutic efficacy of 2L-Rap-hLL1-γ4P in Daudi human xenograft model of NHL. (A) Treatment of Daudi lymphoma with 2L-Rap-hLL1-γ4P. SCID mice (8 to 10 mice per group) were inoculated intravenously with 1.5 × 10⁷ Daudi cells. After 1 day, mice were treated with a single bolus injection of 1 μg(×), 5 μg(▪), 15μg(▴), 30 μg (▾), 40 μg(♦), or 50 μg(•) of 2L-Rap-hLL1-γ4P. Control groups were injected with component proteins equivalent to 50 μg of the immunotoxin (^*) or PBS (□) only. (B) Specific targeting of 2L-Rap-hLL1-γ4P in Daudi lymhoma xenograft model. SCID mice (7 to 8 per group) were inoculated intravenously with 1.5 × 10⁷ Daudi cells. After 1 day, mice were treated with a single bolus intravenous injection of 15 μg 2L-Rap-hLL1-γ4P (•). Control animals received saline (□), 13 μg naked hLL1 (○), 2 μg rRap (⋄), a mixture of naked hLL1 and rRap (▵), and nonspecific immunotoxin 2L-Rap-hRS7 (^*).